enVVeno Medical (NVNO) Common Equity (2017 - 2026)

enVVeno Medical's Common Equity history runs 10 years deep, the most recent figure standing at $23.7 million for Q1 2026.

• On a quarterly basis, Common Equity fell 38.01% year-over-year to $23.7 million in Q1 2026; TTM through Mar 2026 was $23.7 million, a 38.01% decrease from a year earlier, with the FY2025 full-year figure at $27.1 million, down 35.65% from the prior year.
• Common Equity declined to $23.7 million in Q1 2026 per NVNO's latest filing, from $27.1 million in the prior quarter.
• Across five years, Common Equity topped out at $51.3 million in Q1 2022 and bottomed at $23.7 million in Q1 2026.
• The 5-year median for Common Equity is $38.4 million (2024), against an average of $37.4 million.
• Across the five-year window, Common Equity tumbled 41.61% in 2023 and surged 90.13% in 2024, its largest moves.
• Year by year, Common Equity stood at $38.7 million in 2022, then climbed by 19.29% to $46.2 million in 2023, then dropped by 8.75% to $42.2 million in 2024, then sank by 35.65% to $27.1 million in 2025, then slipped by 12.47% to $23.7 million in 2026.
• Per Business Quant, the three latest NVNO Common Equity figures stand at $23.7 million (Q1 2026), $27.1 million (Q4 2025), and $29.4 million (Q3 2025).